| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.79 [0.67, 0.95] | | < 1 | | 67% | 5 studies (5/-) | 99.5 % | some concern | serious | moderate | crucial | - |
| deaths (OS) (extension) | 0.66 [0.55, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.68 [0.57, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.59 [0.49, 0.72] | | < 1 | | 55% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 2.09 [1.70, 2.57] | | > 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.38 [0.18, 0.82] | | < 1 | | 77% | 4 studies (4/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.65 [0.32, 1.34] | | < 1 | | 94% | 4 studies (4/-) | 87.7 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.97 [0.44, 2.14] | | < 1 | | 72% | 4 studies (4/-) | 52.8 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.06 [0.68, 1.64] | | < 1 | | 61% | 4 studies (4/-) | 40.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.24 [0.65, 2.36] | | < 1 | | 70% | 3 studies (3/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.20 [0.60, 2.40] | | < 1 | | 89% | 3 studies (3/-) | 30.4 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.13 [0.53, 2.40] | | < 1 | | 88% | 3 studies (3/-) | 37.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.48 [0.18, 1.29] | | < 1 | | 95% | 3 studies (3/-) | 92.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.65 [0.28, 1.51] | | < 1 | | 95% | 3 studies (3/-) | 84.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.20 [0.55, 2.61] | | < 1 | | 0% | 3 studies (3/-) | 32.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.39 [0.54, 3.55] | | < 1 | | 90% | 3 studies (3/-) | 24.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.47 [1.40, 4.37] | | < 1 | | 55% | 3 studies (3/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 4.76 [0.80, 28.38] | | < 1 | | 0% | 3 studies (3/-) | 4.4 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.06, 15.24] | | < 1 | | 0% | 2 studies (2/-) | 51.4 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.05 [0.00, 0.78] | | < 1 | | 82% | 3 studies (3/-) | 98.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.21 [0.07, 0.60] | | < 1 | | 0% | 3 studies (3/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 5.14 [1.04, 25.43] | | < 1 | | 0% | 4 studies (4/-) | 2.3 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.58 [0.07, 4.48] | | < 1 | | 0% | 3 studies (3/-) | 69.9 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.76 [0.31, 1.87] | | < 1 | | 0% | 3 studies (3/-) | 72.5 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.41 [0.11, 18.45] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 2.71 [1.00, 7.33] | | < 1 | | 15% | 5 studies (5/-) | 2.5 % | some concern | serious | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 1.30 [0.58, 2.92] | | < 1 | | 28% | 3 studies (3/-) | 26.4 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.38 [0.60, 3.15] | | < 1 | | 0% | 1 study (1/-) | 22.3 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.29 [0.68, 27.08] | | < 1 | | 0% | 3 studies (3/-) | 6.2 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.01 [0.15, 6.68] | | < 1 | | 0% | 4 studies (4/-) | 49.4 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.41 [0.11, 18.45] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.21 [0.48, 10.15] | | < 1 | | 0% | 5 studies (5/-) | 15.4 % | some concern | serious | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.75 [0.15, 19.96] | | < 1 | | 0% | 2 studies (2/-) | 32.7 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.93 [0.48, 7.72] | | < 1 | | 0% | 3 studies (3/-) | 17.7 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 7.55 [2.24, 25.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 3.77 [0.61, 23.22] | | < 1 | | 0% | 2 studies (2/-) | 7.7 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.35 [0.05, 2.50] | | < 1 | | 62% | 3 studies (3/-) | 85.1 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.96 [0.10, 9.20] | | < 1 | | 0% | 3 studies (3/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.07 [0.00, 1.34] | | < 1 | | 88% | 3 studies (3/-) | 95.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.18 [0.96, 10.52] | | < 1 | | 0% | 4 studies (4/-) | 3.0 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.60 [0.26, 9.78] | | < 1 | | 0% | 4 studies (4/-) | 30.5 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.59 [0.36, 7.07] | | < 1 | | 38% | 5 studies (5/-) | 27.1 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.11 [0.01, 2.18] | | < 1 | | 82% | 3 studies (3/-) | 92.3 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.24 [0.03, 2.19] | | < 1 | | 65% | 3 studies (3/-) | 89.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.52 [0.07, 4.08] | | < 1 | | 0% | 3 studies (3/-) | 73.4 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.10 [0.05, 0.22] | | < 1 | | 47% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.89 [0.49, 1.61] | | < 1 | | 0% | 3 studies (3/-) | 65.2 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 0.48 [0.13, 1.77] | | < 1 | | 0% | 3 studies (3/-) | 86.3 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.32 [0.25, 6.88] | | < 1 | | 0% | 3 studies (3/-) | 37.0 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 1.42 [0.11, 18.46] | | < 1 | | 0% | 2 studies (2/-) | 39.6 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 1.38 [0.59, 3.25] | | < 1 | | 0% | 3 studies (3/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.61 [0.12, 2.98] | | < 1 | | 67% | 3 studies (3/-) | 73.0 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 1.40 [0.68, 2.85] | | < 1 | | 0% | 3 studies (3/-) | 18.0 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 1.15 [0.63, 2.10] | | < 1 | | 0% | 3 studies (3/-) | 32.7 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.06 [0.00, 1.03] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 4.87 [0.57, 41.91] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 5.82 [0.29, 116.64] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
| Increased Lipase Level AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.10 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
| myocarditis AE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.37 [0.13, 1.04] | | < 1 | | 0% | 3 studies (3/-) | 97.1 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.05 [0.02, 0.13] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia (AE grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.96 [0.06, 15.46] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 0.77 [0.20, 2.88] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.95 [0.06, 15.24] | | < 1 | | 0% | 2 studies (2/-) | 51.4 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 2.96 [0.27, 32.07] | | < 1 | | 0% | 2 studies (2/-) | 18.7 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 2.47 [0.54, 11.26] | | < 1 | | 0% | 3 studies (3/-) | 12.1 % | some concern | not evaluable | moderate | non important | - |
| Rash maculopapular AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.01, 0.13] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.33 [0.12, 0.90] | | < 1 | | 0% | 3 studies (3/-) | 98.5 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 2.67 [0.63, 11.38] | | < 1 | | 0% | 3 studies (3/-) | 9.3 % | some concern | not evaluable | moderate | non important | - |
